Algert Global LLC Has $1.24 Million Holdings in CytomX Therapeutics Inc (CTMX)

Algert Global LLC grew its position in CytomX Therapeutics Inc (NASDAQ:CTMX) by 208.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 66,809 shares of the biotechnology company’s stock after acquiring an additional 45,159 shares during the period. Algert Global LLC owned about 0.15% of CytomX Therapeutics worth $1,236,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the business. Great West Life Assurance Co. Can raised its position in shares of CytomX Therapeutics by 174.6% in the second quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 3,143 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of CytomX Therapeutics by 36.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 12,917 shares of the biotechnology company’s stock worth $295,000 after acquiring an additional 3,432 shares during the period. TD Asset Management Inc. raised its position in shares of CytomX Therapeutics by 8.5% in the second quarter. TD Asset Management Inc. now owns 47,200 shares of the biotechnology company’s stock worth $1,079,000 after acquiring an additional 3,700 shares during the period. Wells Fargo & Company MN raised its position in shares of CytomX Therapeutics by 4.4% in the third quarter. Wells Fargo & Company MN now owns 94,985 shares of the biotechnology company’s stock worth $1,757,000 after acquiring an additional 4,020 shares during the period. Finally, AMP Capital Investors Ltd raised its position in shares of CytomX Therapeutics by 6.1% in the second quarter. AMP Capital Investors Ltd now owns 70,709 shares of the biotechnology company’s stock worth $1,616,000 after acquiring an additional 4,088 shares during the period. Institutional investors and hedge funds own 83.79% of the company’s stock.

In related news, insider Sean A. Mccarthy sold 6,526 shares of the company’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $15.00, for a total transaction of $97,890.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Debanjan Ray sold 3,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $15.00, for a total transaction of $45,000.00. Following the sale, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at approximately $133,920. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,526 shares of company stock valued at $198,270. Insiders own 8.50% of the company’s stock.

CTMX has been the subject of a number of analyst reports. ValuEngine downgraded shares of CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. Piper Jaffray Companies initiated coverage on shares of CytomX Therapeutics in a research report on Sunday, December 2nd. They issued an “overweight” rating and a $13.24 price objective for the company. BidaskClub downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. HC Wainwright set a $32.00 price target on shares of CytomX Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 9th. Finally, Zacks Investment Research downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $32.47.

CTMX opened at $14.09 on Friday. CytomX Therapeutics Inc has a twelve month low of $12.51 and a twelve month high of $35.00. The stock has a market cap of $622.45 million, a P/E ratio of -12.15 and a beta of 1.43.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.11). CytomX Therapeutics had a negative return on equity of 65.03% and a negative net margin of 68.90%. The company had revenue of $12.51 million for the quarter, compared to analyst estimates of $16.42 million. Analysts forecast that CytomX Therapeutics Inc will post -1.78 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Algert Global LLC Has $1.24 Million Holdings in CytomX Therapeutics Inc (CTMX)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/12/08/algert-global-llc-has-1-24-million-holdings-in-cytomx-therapeutics-inc-ctmx.html.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: What is a Call Option?

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply